[go: up one dir, main page]

EP1748075A1 - Vaccin chimiokine-antigene recombinant - Google Patents

Vaccin chimiokine-antigene recombinant Download PDF

Info

Publication number
EP1748075A1
EP1748075A1 EP05745450A EP05745450A EP1748075A1 EP 1748075 A1 EP1748075 A1 EP 1748075A1 EP 05745450 A EP05745450 A EP 05745450A EP 05745450 A EP05745450 A EP 05745450A EP 1748075 A1 EP1748075 A1 EP 1748075A1
Authority
EP
European Patent Office
Prior art keywords
gene
sequence
fragment
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05745450A
Other languages
German (de)
English (en)
Other versions
EP1748075A4 (fr
EP1748075A8 (fr
EP1748075B1 (fr
Inventor
Shuren Zhang
Chen Lin
Wenxin Sun
Hanjun Tan
Chunxia Zhou
Xiao Liang
Dongmei Wang
Wenbo Ma
Xueyan Zhang
Ming Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Hospital and Institute of CAMS and PUMC
Original Assignee
Dongguan Bio-Engineering Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Bio-Engineering Development Co Ltd filed Critical Dongguan Bio-Engineering Development Co Ltd
Priority to PL05745450T priority Critical patent/PL1748075T3/pl
Publication of EP1748075A1 publication Critical patent/EP1748075A1/fr
Publication of EP1748075A8 publication Critical patent/EP1748075A8/fr
Publication of EP1748075A4 publication Critical patent/EP1748075A4/fr
Application granted granted Critical
Publication of EP1748075B1 publication Critical patent/EP1748075B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Definitions

  • the invention relates to a new recombinant gene sequence, a fusion protein expressed from the gene, and vaccines produced with the gene, as well as to different gene vaccines produced by replacing the antigen gene in the recombinant sequence, or to use of the expression products as fusion peptide vaccines.
  • SLC Human secondary lymphoid tissue chemokine
  • anti-tumor immunoreaction can be enhanced by immunizing mice with DCs that are transfected with recombinant retrovirus vector containing genes encoding IgG Fc fragment and tumor antigen.
  • the mechanism is that the fusion protein secreted and expressed from DC is re-captured by DCs through the Fc receptor (FcR), and then the fusion protein epitope is presented to T helper cells (Th) through MHC class II molecules and cross presented to cytotoxic T lymphocytes (CTL) through MHC class I molecules, through which anti-tumor humoral-and-cellular immunity is induced systematically.
  • FcR Fc receptor
  • Th T helper cells
  • CTL cytotoxic T lymphocytes
  • one aim of the invention is to provide a new recombinant gene sequence.
  • Another aim of the invention is to provide a fusion protein expressed by the recombinant gene sequence.
  • Another aim of the invention is to provide a gene vaccine of the fusion protein encoded by the recombinant gene sequence according to the invention.
  • the aim of the invention is to provide a recombinant tumor chemotactic antigen gene vaccine.
  • the invention relates to a recombinant gene sequence, comprising human SLC gene, antigen gene, and IgG1-Fc fragment gene, wherein the SLC gene is linked upstream to the antigen gene, and the IgG1-Fc fragment gene is linked downstream to the antigen gene.
  • the said antigen gene comprises Her2/neu, P53, PSA, PAP, PSM, MAGE1, MAGE2, MAGE3, BAGE, GAGE1, GAGE 2, CAG3, RAGE, NY-ESO-1, Tyrosinase, CEA, Ig idiotype, gp100, melan A, gp75, TRP-1, TRP-2, CDK4, CASP-8, ras, bcr/abl, MUC-1, and genes encoding the proteins related with the viruses of HCV, HIV and pathogenic microorganisms.
  • EcoRI restrictive endonuclease sites and genes of three glycins are present between SLC gene and antigen gene, and EcoRV restrictive endonuclease sites and genes of five glycins are present between antigen gene and IgG1-Fc fragment gene.
  • the recombinant gene sequence of the invention comprises SEQ ID NO:1 and SEQ ID NO: 12.
  • the invention also relates to an amino acid sequence encoded by the recombinant gene sequence according to the invention.
  • the said amino acid sequence comprises SEQ ID NO: 2.
  • the invention also relates to an amino acid sequence encoded by SEQ ID NO: 12.
  • the said amino acid sequence is SEQ ID NO: 13.
  • the invention also relates to a gene vaccine, comprising the recombinant gene sequence of the invention.
  • the invention also relates to a gene vaccine.
  • the gene vaccine comprises SEQ ID NO: 1, SEQ ID NO: 12 and the corresponding amino acid sequences.
  • the invention relates to a recombinant gene sequence, comprising human SLC gene, antigen gene, and IgG1-Fc fragment gene, wherein the SLC gene is linked upstream to the antigen gene, and the IgG1-Fc fragment gene is linked downstream to the antigen gene.
  • the said antigen gene comprises Her2/neu, P53, PSA, PAP, PSM, MAGE1, MAGE2, MAGE3, BAGE, GAGE1, GAGE 2, CAG3, RAGE, NY-ESO-1, Tyrosinase, CEA, Ig idiotype, gp100, melan A, gp75, TRP-1, TRP-2, CDK4, CASP-8, ras, bcr/abl, MUC-1, and other genes encoding the proteins related with the viruses of HCV, HIV and other pathogenic microorganisms.
  • EcoRI restrictive endonuclease sites and genes of three glycins are present between SLC gene and antigen gene of the invention, and EcoRV restrictive endonuclease sites and genes of five glycins are present between antigen gene and IgG1-Fc fragment gene.
  • This invention also relates to the use of the recombinant gene sequence of the invention in preparing gene vaccines.
  • a gene vaccine comprising the gene sequence of the invention, in particular, SEQ ID NO: 1, SEQ ID NO: 12 and the corresponding amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 13.
  • this invention relates to a recombinant gene sequence, comprising human SLC gene, antigen gene and IgG1-Fc fragment gene (See Figure 13).
  • SLC gene is linked upstream to the antigen gene, and the EcoRI restrictive endonuclease sites and genes of three glycins are introduced.
  • IgG1-Fc fragment gene is linked downstream to the antigen gene, and EcoRV restrictive endonuclease sites and genes of five glycins are introduced.
  • this invention relates to a recombinant gene comprising the nucleic aicd sequence of SEQ ID NO: 1.
  • the nucleic acid sequence of SEQ ID NO: 1 is the artificially ligated sequence of SLC-Her2/P53-Fc, wherein, the SLC gene locates from position 1 to position 402 of the nucleic acid; the Her2 ligating gene locates from position 418 to position 711 of the nucleic acid.
  • the nucleic acids from position 418 to position 444 in the recombinant gene are corresponding to those from position 1105 to position 1131 in the open reading frame (ORF) of Her2/neu gene.
  • the nucleic acids from position 445 to position 546 in the recombinant gene are corresponding to those from position 244 to position 345 in the open reading frame (ORF) of Her2/neu gene, wherein a mutation from G to C at position 250 is introduced.
  • the nucleic acids from position 547 to position 711 in the recombinant gene are corresponding to those from position 1333 to position 1479 in the ORF of Her2/neu gene.
  • part of P53 gene locates from position 712 to position 1113, corresponding to the nucleic acids from position 475 to position 876 of p53 ORF.
  • the IgG Fc gene (including introns) locates from position 1147 to position 2057 in the recombinant gene, wherein the two introns locates from position 1189 to position 1309, and from position 1640 to position 1739, respectively.
  • the nucleic acid sequence from position 1147 to position 1189 is the C-region hinge sequence.
  • the nucleic acid sequence from position 1310 to position 1369 is for CH2, and nucleic acid sequence from position 1740 to position 2057 is for CH3.
  • Three genes of glycins and EcoRI restrictive endonuclease sites are introduced upstream to Her2/P53 fragment, and five genes of glycins and EcoRV restrictive endonuclease sites are introduced downstream to Her2/P53.
  • 3 ⁇ 5 genes of glycins are introduced upstream and downstream to the antigen gene. The effect of the glycin genes is to prevent the recombinant antigen from interfering the three-dimensional structure.
  • This invention also relates to an amino acid sequence (612aa ⁇ mat589aa ⁇ of SEQ ID NO: 2 encoded by nucleotide sequence of SEQ ID NO: 1, wherein SEQ ID NO: 1 is an artificially recombinant SLC-Her2/P53-Fc gene.
  • SLC fragment locates from position 1 to position 134
  • three glycins locate from position 135 to position 137
  • part of Her2 peptide locates from position 140 to position 237.
  • the amino acids from position 140 to position 148 in the fusion protein are corresponding to those from position 369 to position 377 in Her2/neu.
  • the amino acids from position 149 to position 182 in the fusion protein are corresponding to those from position 82 to position 115 in Her2/neu, wherein a mutation from V to L is introduced at position 84.
  • the amino acids from position 183 to position 238 in the fusion protein are corresponding to those from position 445 to position 499 in Her2/neu.
  • Part of P53 peptide locates from position 238 to position 371 in the fusion protein (corresponding to the amino acids from position 159 to position 292 in P53 natural form).
  • the five glycins locate from position 374 to position 378.
  • the IgG Fc locates from position 383 to position 612, wherein the sequence from position 383 to position 396 is for C-region hinge, the sequence from position 397 to position 506 is for CH2, and the sequence from position 507 to position 612 is for CH3.
  • This invention also relates to another recombinant gene for prostate cancer vaccine, the sequence of which is shown by SEQ ID NO: 12.
  • the nucleotide sequence of SEQ ID NO: 12 is a sequence of artificially ligated SLC-PSM-mPAP-PSA-Fc (SLC-3P-Fc) gene, wherein only partial sequences of PSM (human Prostate Specific Membrane Antigen), mPAP ⁇ mouse Prostatic Acid Phosphatase ⁇ , and PSA (human Prostate Specific Antigen) are introduced.
  • SLC gene locates from position 1 to position 402; Part of PSM gene locates from position 418 to position 603, corresponding to the sequence from position 1987 to position 2172 in the PSM open reading frame (ORF);
  • the mPAP gene locates from position 604 to position 759, corresponding to the sequence from position 328 to position 484 in mPAP ORF;
  • PSA gene locates from position 760 to position 981, corresponding to the sequence from position 151 to position 372 in PSA ORF;
  • the IgG Fc gene (including introns) locates from position 1003 to position 1925, wherein the two introns locate from position 1057 to position 1177 and from position 1508 to position 1607, respectively.
  • Genes for three glycins and EcoRI restrictive endonuclease sites are introduced upstream to 3P, and genes for five glycins and EcoRV restrictive endonuclease sites are introduced downstream to 3P.
  • This invention also relates to the amino acid sequence of SEQ ID NO: 13 encoded by nucleotide sequence of SEQ ID NO: 12. Namely, the invention relates to the amino acid sequence (568aa) corresponding to the artificially recombinant SLC-3P-Fc gene.
  • SLC locates from position 1 to position 134
  • three glycins locates from position 135 to position 137
  • PSM locates from position 140 to position 201
  • part of mPAP peptide locates from position 202 to position 253
  • part of PSA peptide locates from position 254 to position 327
  • five glycins locates from position 374 to position 378
  • IgG1-Fc locates from position 335 to position 568.
  • This invention also relates to the use of the recombinant gene sequence of the invention, including SEQ ID NO: 1, in preparing vaccines.
  • the strategy for the chemotactic antigen of the invention is as follow: linking the chemokine of SLC upstream to the antigen and linking the Fc of IgG downstream to the antigen; introducing the three parts-fused gene directly into healthy or tumor tissues for expression and secretion; and forming a two-part conjoined body through Fc hinge region.
  • the said recombinant protein actively attracts DC and T cells through the chemoatactic activity of SLC in vivo.
  • DC captures the fusion protein with high efficiency through pinocytosis, especially with the help of Fc receptor and SLC receptor CCR7. Meanwhile, DC carries the antigen into the cell.
  • DC can be activated by the combination of Fc fragment with Fc receptor of DC.
  • SLC can actively abstract DC and T lymphocytes, as well as promotes the secretion of cytokines such as IL-12, IFN- ⁇ , and interferon-induced protein (IP-10), promotes the development of Th1, down-regulats the production of TGF- ⁇ and VEGF.
  • cytokines such as IL-12, IFN- ⁇ , and interferon-induced protein (IP-10)
  • IP-10 interferon-induced protein
  • recombinant genes are used, but not intending to restrict the invention.
  • the study for control has revealed that either in the form of plasmid or in the form fusion protein, the recombinant chemokine antigen can be produced industrially.
  • the step of preparation of DC has been omitted in the application.
  • DC can be targeted with high efficiency in vivo.
  • introduction of restrictive endonuclease sites into the two ends of antigen gene makes it possible to replace the antigen to produce various chemokine antigen vaccines against tumorous or non-tumorous diseases.
  • a new chemokine antigen vaccine can be produced by replacing the HP antigen in SLC-HP-Fc with prostate cancer-relating antigen.
  • the recombinant gene can be constructed into the eukaryotic vectors by using direct injection of the plasmid into the body or tumor. Other techniques such as gene gun and electrical pulse can enhance the transfection rate and expression efficiency. Constructed recombinant virus, such as retrovirus, adenovirus, adeno-associated virus, vaccine virus, herpes simplex virus and so on, can also be used as vaccine for in vivo injection.
  • the plasmid can be transfected into Eukaryotic cell (for example, CHO) and cultured in vitro for secretion and expression. Through the Fc fragment, the fusion protein can be easily and efficiently isolated and purified by Affinity Chromatography method, and can be used as protein vaccine.
  • the mRNA was extracted from the lymph node of patients suffering from cancer.
  • the KpnI restrictive endonuclease site was added to the SLC forward primer (5'-c ggtacc acagacatggctcagtcac-3') and the sequence encoding three glycins and EcoRI restrictive endonuclease site was added to the SLC reverse primer (5'-t gaattc tcctcctctggccctttagg-3').
  • the SLC gene was acquired by RT-PCR amplification.
  • the acquired fragment was purified and inserted into pUCmT vector (pUC-SLC) for sequencing. The result shows that the sequence of the acquired fragment was in accordance with the designed sequence (the underlined fragment).
  • sequencing of the PCR products was performed by using 377 DNA sequencer (ABI company) by four-colored fluorescence terminator sequencing method based on SANGER dideoxynucleotide chain termination method.
  • the sequence from position 36 to position 464 is the sequence of the cloned fragment of the invention (Refer to SEQ ID NO: 3).
  • the used forward primer is 5'-a gaattc aagatctttgggagcctggcatttctgggctacctgctcatcgctca c-3', having EcoRI restrictive endonuclease site
  • the used reverse primer is 5'-gatgcccagcccttgca gggccagggcatagttgtc-3'.
  • the plasmid containing extra cellular segment of neu gene was adopted as template and the fragment corresponding to amino acid sequence from position 82 to position 115 was amplified, wherein the amino acid V at position 103 was replaced by amino acid L.
  • the second fragment was acquired as follows: the forward primer was 5'-ctgcaagggctgggcatc-3', and the reverse primer having NcoI restrictive endonuclease site was 5'-t ccatgg cccggttggcagtgtggag-3'.
  • the fragment corresponding to amino acid sequence from position 445 to position 499 was amplified.
  • the two PCR products were collected and linked together in a PCR system. Further, the resulted fragment was used as template, by using the forward primer of the first fragment and the reverse primer of the second fragment; a fusion gene with 294bp in size was amplified. Then the resulted fusion gene was inserted into pUCmT vector (pUC-Her2P) and sequenced. The result indicates that the sequence of the obtained fusion gene is in accordance with the designed sequence (the underlined sequence).
  • a 402bp gene fragment encoding the amino acids from position 156 to position 289 in p53 protein was cloned from the plasmid containing the whole length of p53 gene.
  • the primers used were as follows: forward primer with one NcoI restrictive endonuclease site was 5'-acc atg gcc atc tac aag cag tca cag cac atg ac-3'; reverse primer with one EcoRV restrictive endonuclease site was 5'-tga tat ctt tct tgc gga gat tct ctt c-3'.
  • the obtained fragment was inserted into pUCmT vector (pUC-p53P) for sequencing. The result indicates that the sequence of the obtained fragment is in accordance with the expected sequence (the underlined segment).
  • the smaller fragment cut from pUC-Her2P by EcoRI/NcoI and the smaller fragment cut from pUC-p53P by NcoI/EcoRV were ligated with the larger fragment cut from pcDNA3z by EcoRI/EcoRV to construct a plasmid of pcDNA-Her2/p53, also called pcDNA-HP.
  • HP means a gene ligated by Her2/neu and p53.
  • the artificially ligated Her2/neu-p53 fragment contains genes encoding HLA-I and HLA-II molecule-binding peptide.
  • the forward primer was N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the reverse primer was N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl
  • the last 15 bases at the 3' ends of each primer are complementary to each other.
  • the PCR product was obtained in a system with the mixture of the two primers at the ratio of 1:1, Taq DNA polymerase and dNTP at 45 °C for renaturing and elongation.
  • the purified product was inserted into pUCmT vector for sequencing. The result shows that the sequence of the obtained product is in accordance with the designed sequence.
  • the underlined sequence indicates the synthesized multiple cloning sites.
  • the final resulting multiple cloning sites were: "NheI-HindIII-Kpn1 -BamHI-EcoRI-EcoRV-Glysinex5 -Xbal- Xho1- Apa1-Sma1- Hpa1-Pme1".
  • NheI/PmeI cut the cloned plasmid and a fragment about 100bp in size was obtained. Then, the fragment was ligated with the larger fragment cut from pcDNA3. 1 by NheI/PmeI to construct a new vector named pcDNAf.
  • the Fc fragment was cut from IgG1 Fc-containing plasmid by XbaI/ApaI restrictive endonucleases and inserted into pcDNAf vector, wherein the pcDNAf vector was treated with the same endonuclease.
  • the resulted construction was named as PcDNA-Fc.
  • the sequence of IgG1 Fc was confirmed by sequencing the resulted plasmid.
  • the Fc fragment with 900bp in size was amplified from plasmid containing IgG1 Fc gene by PCR and inserted into pUCmT vector for sequencing.
  • the primers used in the amplification were: forward primer: 5'-gaattcggagttaacgagcccaaatcttg-3'; reverse primer: 5'-gggccctcatttacccggagac-3'.
  • the result of sequencing reveals that the plasmid contained the hinge region, CH2 and CH3 of IgG1. That is to say, the plasmid contained Fc fragment (See the underlined sequence). The result is indicated in SEQ ID NO: 7, wherein the sequence from position 78 to position 991 is the inventive sequence.
  • the larger fragment cut from pcDNA-HP with KpnI/EcoRI was linked with the smaller fragment cut from pUC-SLC with KpnI/EcoRI to construct pcDNA-SLC-HP.
  • the smaller fragment cut from pcDNA-SLC-HP by KpnI/EcoRV was linked with the larger fragment cut from pcDNA-Fc by KpnI/EcoRV to construct pcDNA-SLC-HP-Fc (also named as pSLC-HP-Fc).
  • Example 7 Detection of cellular and secreted recombinant protein in cells transfected with gene vaccine by Western Blot
  • the recombinant plasmid of pSLC-HP-Fc was transfected into B16-F10 cells by using the method of liposome.
  • the positive clones were selected by G418. Cultured the cells in serum-free 1640 medium for 24 hours, and then collected and concentrated the supernant.
  • the method of Western Blot was used to detect the expression of the fusion protein.
  • the used primary antibody was rabbit-anti-human p53 polyclonal antibody, and the second antibody was HRP-conjugated goat-anti-rabbit antibody.
  • the blots were visualized with ECL-Plus chemiluminescent detection kit (Amersham Pharmacia Biotech). Finally, the film was exposed to X-ray.
  • the result indicates that the expression of fusion protein can be detected in the supernant and cell lysate of B 16-F10 cells transfected with pSLC-HP-Fc.
  • the molecular weight is in accordance with what expected (See Figure 4). It has been verified that the sequence of fusion protein is SEQ ID NO: 2.
  • RT-PCR was performed by using a forward primer (5'-ACTCGAGAT GAAGACATACAGTGTATC-3') and a reverse primer (5'-TGATATCTTAGGCTAC TTCACTCAAAG-3').
  • the fragment was purified and recovered by the method of Glass Milk.
  • the purified fragment was ligated with pUCm-T vector to construct pUCm-hPSM.
  • the positive clone was picked up and sequenced. The result is in accordance with what is expected. Please refer to SEQ ID NO: 8, the obtained gene fragment is corresponding to the sequence from position 1864 to position 2253 in human PSM ORF.
  • the sequence from position 229 to position 618 in the obtained sequence is the inventive sequence.
  • RT-PCR was performed by using a forward primer (5'-TCTCGAGGGC GGTGTTCTGGTGCA-3') and a reverse primer (5'-AGATATCATGTCC AGCGTCCAGCAC-3'). After electrophoresis, the band with about 600bp in size was cut out. The fragment was purified and recovered by the method of Glass Milk. The obtained fragment was inserted into pUCm-T to construct pUCm-PSA. The positive clone was picked up and sequenced. The result is indicated in SEQ ID NO: 9. The obtained gene fragment is corresponding to the sequence from position 151 to position 609 of human PSA ORF. The sequence from position 45 to position 503 in the obtained sequence is the inventive sequence.
  • the hPSM gene fragment was cloned from pUCm-hPSM plasmid by PCR with the following primers: forward primer corresponding to the sequence from position 1987 to position 2007 of hPSM ORF (EcoRI restrictive endonuclease site was introduced) was 5'-AGAATTCATGATGAATGATCAACTCATG-3'; reverse primer was 5'- AGCACTCATCAAAGTCCT GGCCTTGGAAGGGTCCAC-3' ⁇ the underlined section was corresponding to the sequence from position 328 to position 345 of mPAP ORF, and the remains section was corresponding to the sequence from position 2155 to position 2172 of hPSM ORF ⁇ .
  • the obtained hPSM fragment was cut out and purified by the method of Glass Milk.
  • the mPAP gene fragment was cloned from pUCm- mPAP plasmid by PCR with the following primers: forward primer corresponding to the sequence from position 328 to position 348 of mPAP ORF was 5'-AGGACTTTGATGAGTGCTATG-3'; the reverse primer corresponding to the sequence from position 463 to position 483 of mPAP ORF was 5'-AGGGCAGTCTCTGAAAGGCAG-3'.
  • the obtained mPAP fragment was cut out and purified by the method of Glass Milk.
  • the hPSA gene fragment was cloned from pUCm-hPSA plasmid by PCR with the following primers: the forward primer was 5'- CCTTTCAGAGACTGCCCT GGCGGTGTTC TGGTGCAC-3' (the underlined section was corresponding to the sequence from position 466 to position 483 of mPAP ORF, and the remain section was corresponding to the sequence from position 151 to position 168 of hPSA ORF); the reverse primer was 5'-AGATATCGAGCAGCATGAGGTCGT-3'. After electrophoresis, the obtained hPSA fragment was cut out and purified by the method of Glass Milk.
  • the primer of 5'-AGAATTCATGATGAATGATCAACTCATG-3' was used to amplify hPSM and the primer of 5'-AGGGCAGTCTCTGAAAGGCAG-3' was used to amplify mPAP individually in a 25 ⁇ l system for 10 cycles to rich the single chains. Then, the two systems were mixed to further perform PCR in a 50 ⁇ l system for 18 cycles. After electrophoresis, the obtained hPSM-mPAP fragment with 352bp in size was cut out and purified by the method of Glass Milk.
  • the primer of 5'-AGGACTTTGATGAGTGCTATG -3' ⁇ corresponding to the sequence from position 328 to position 348 of mPAP ORF ⁇ was used to amplify mPAP and use the primer of 5'-AGATATCGAGCAGCATGAGGTCGTG-3' ⁇ corresponding to the sequence from position 355 to position 372 of PSA ORF ⁇ to amplify hPSA individually in a 25 ⁇ l system for 10 cycles to rich the single chains. Then, the two systems were mixed to further perform PCR in the 50 ⁇ l system for 18 cycles. After electrophoresis, the obtained mPAP-hPSA fragment with 378bp in size was cut out and purified by the method of Glass Milk.
  • the primer of 5'-AGAATTCATGATGAATGATCAACTCATG-3' was used to amplify hPSM-mPAP and the primer of 5'-AGATATCGAGCAGCATGAGGTCGTG-3' was used to amplify mPAP-hPSA individually in a 25 ⁇ l system for 10 cycles to rich the single chains. Then, the two systems were mixed to further perform PCR in the 50ul system for 18 cycles. After electrophoresis, the obtained hPSM-mPAP-hPSA fragment with 564bp in size was cut out and purified by the method of Glass Milk. The resulted fragment was inserted into pUCm-TV vector for sequencing. The result was in accordance with what was expected. See SEQ ID NO: 11, wherein the sequence from position 54 to position 629 is the inventive sequence.
  • the plasmid containing correct 3P gene sequence (3P means a PSM-PAP-PSA fusion gene with 564bp in size encoding 188 amino acids) was cut by EcoRI/EcoRV restrictive endonucleases. The obtained smaller 3P fragment was ligated with EcoRI/EcoRV-cut pSLC-HP-Fc vector to construct pSLC-3P-Fc (See Figure 12).
  • SLC-3P-Fc gene is shown in SEQ ID NO: 12, which is corresponding to amino acid sequence shown in SEQ ID NO: 13.
  • Test 1 Detection of the immune cells-chemoatactic activity of fusion protein by Boyden chamber
  • the Chamber was purchased from Neuro Probe Co.
  • the lower wells of the chamber were filled with 27 ⁇ l conditioned culture medium, whereas the upper wells were filled with 50 ⁇ l of 1 ⁇ 10 6 /ml PBMC cell suspension.
  • the lower and upper wells were separated by a polycarbonate filter (Neuro Probe) with 5 ⁇ m pore size.
  • the chamber was incubated at 37°C with 5% CO 2 for 4 h. D.
  • the filter was unloaded and the cells were scraped off from the upper side of filter, following by washing, fixing and staining the filter.
  • the migrated cells in five randomly selected high power ( ⁇ 200) fields were counted.
  • the value of CI of negative group was 1.
  • Table 1 Detection of the chemoatactic activity of fusion protein Groups Counts of chemoatactic cells CI P value Negative control 34 ⁇ 10. 4 1 Control vector 44.6 ⁇ 11.9 1.
  • the level of the chemoatactic activity of serum-free supernant from cells transfected with pSLC-HP-Fc is significantly higher than others, indicating that after transfection, the plasmid can be expressed and the expressed protein has activity.
  • the level of chemoatactic ability of pSLC-HP-Fc transfecting cells is similar to that of pSLC transfecting cells, indicating that the fusion protein does affect the activity of SLC.
  • the plasmids (nude gene) were loaded on gold particles and coated onto the inner surface of Tefzel tubing that was cut into proper segments as bullet to deliver 1 ⁇ g DNA according to the BioRad's manual.
  • control vector pSLC-Fc
  • psig-HP the plasmid expressing HP containing the SLC signal peptide
  • pSLC-HP the plasmid expressing HP containing the SLC signal peptide
  • mice 14 days and 7 days before tumor inoculation, the mice were vaccinated twice with pSLC-HP-Fc or control vectors at the abdomen skin. On day 0, each mouse was inoculated with 5 ⁇ 10 4 B 16F 10 tumor cells (The B16F 10 cells were transfected with HP gene and selected by G418) in 0.2ml solution. The tumor sizes were recorded 2-3 times per week. The tumor size was calculated as length (cm) ⁇ width (cm 2 ).
  • each mouse was inoculated with 5 ⁇ 10 4 B16F10 tumor cells in 0.2 ml solution.
  • the mice were vaccinated by Gene Gun System.
  • the tumor sizes were recorded 2 ⁇ 3 times per week. The tumor sizes were evaluated as mentioned above.
  • the pSLC-HP-Fc vaccine displays the most effective suppression of tumor growth.
  • the difference between pSLC-HP-Fc and psig-HP-Fc groups is significant ( P ⁇ 0. 05 ).
  • the average survival period of mice is prolonged by pSLC-HP-Fc immunization.
  • the mice in B16 ⁇ pSLC-HP-Fc ⁇ group are inoculated with wild type B16 cells. After three-time pSLC-HP-Fc immunization, the B16 group displays no tumor suppression effect, suggesting that pSLC-HP-Fc induced immune response is specific to HP antigen.
  • lymphocytes derived from chemokine nucleotide vaccine immunized mice showed significant cytotoxicity effect on B 16F 10-HP cells (See Figure 9).
  • E:T ratios 40:1 or 20:1
  • there was still significant difference between the studied vaccine and control vectors P ⁇ 0. 05
  • the vaccine was more powerful to induce CTL activity.
  • HP-specific antibodies in the serum of the immunized mice group was detected by ELISA, 2 and 4 weeks after immunization (pSLC-HP-Fc). Briefly, microtitre plates coated with recombinant p53 proteins were incubated overnight, blocked with 20% Calf Serum, and incubated with primary antibody (serially diluted mouse serum) and secondary antibody (horseradish peroxidase-conjugated goat antimouse IgG) in turn. After washing and visualizing by OPD ⁇ O-Phenylene diamine ⁇ , the OD value was read at 490nm. A monoclonal antibody against p53 was used as a positive control and normal mouse serum was used as a negative control.
  • MNCs mononuclear cells
  • Half of the MNCs were transfected with the plasmid pSLC-HP-Fc using liposome and incubated with untreated MNCs at the ratio of 1:1 at 37 ⁇ with 5% CO2.
  • the viable cells were counted, re-suspended and cultured with different target cells at different E:T ratios in 96-well microplates.
  • the LDH assay (Promega Kits) was used to analyze the cytotoxicity.
  • the pSLC-HP-Fc transfects MNC induced specific CTL to kill tumor cells that overexpress Her2/neu or p53 in a MHC-restricted manner (See Fig 11). That is to say, the specific CTL only significantly kills HLA-A2 + tumor cells that express Her2/neu or p53, indicating the specificity of CTL induced by the chemotactic antigen gene vaccine.
  • mice 5 ⁇ 10 4 B16-3P cancer cells ⁇ pcDNA-3P transfected B16 cancer cells by G418 selection ⁇ were inoculated on the flank of C57BL/6 mice (eight mice each group). The mice were immunized on third, eighth and thirteen day after tumor cell inoculation.
  • the control vector, pSLC-Fc, psig-3P (the plasmid containing with a SLC signal peptide gene upstream to 3P gene) were used as control groups. The tumor sizes and survival periods of mice were observed.
  • the chemokine antigen gene vaccine ⁇ pSLC-3P-Fc ⁇ significantly inhibits the tumor growth (vs control groups P ⁇ 0. 05), and significantly prolongs the survival period (vs control groups P ⁇ 0. 05 ), suggesting change of the antigen in the chemotactic antigen gene vaccine can produce different vaccine against the associated antigen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05745450A 2004-05-10 2005-05-09 Vaccin chimiokine-antigene recombinant Expired - Lifetime EP1748075B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL05745450T PL1748075T3 (pl) 2004-05-10 2005-05-09 Rekombinantowa szczepionka z antygenem chemokiny

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2004100379103A CN100342017C (zh) 2004-05-10 2004-05-10 基因重组趋化抗原疫苗
PCT/CN2005/000639 WO2005108584A1 (fr) 2004-05-10 2005-05-09 Vaccin chimiokine-antigene recombinant

Publications (4)

Publication Number Publication Date
EP1748075A1 true EP1748075A1 (fr) 2007-01-31
EP1748075A8 EP1748075A8 (fr) 2007-09-26
EP1748075A4 EP1748075A4 (fr) 2008-01-02
EP1748075B1 EP1748075B1 (fr) 2010-03-31

Family

ID=35320238

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05745450A Expired - Lifetime EP1748075B1 (fr) 2004-05-10 2005-05-09 Vaccin chimiokine-antigene recombinant

Country Status (12)

Country Link
US (1) US8133873B2 (fr)
EP (1) EP1748075B1 (fr)
JP (1) JP4838238B2 (fr)
CN (1) CN100342017C (fr)
AT (1) ATE462792T1 (fr)
AU (1) AU2005240691B2 (fr)
CA (1) CA2566299C (fr)
DE (1) DE602005020272D1 (fr)
ES (1) ES2343419T3 (fr)
PL (1) PL1748075T3 (fr)
RU (1) RU2396348C2 (fr)
WO (1) WO2005108584A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781700B1 (fr) 2004-08-03 2014-03-19 TransTech Pharma, LLC Protéines hybrides rage et leurs procédés d'utilisation
EP2421892A1 (fr) 2009-04-20 2012-02-29 Pfizer Inc. Contrôle de la glycosylation de protéines, compositions et méthodes associées
CN104877969A (zh) * 2014-12-14 2015-09-02 刘滨磊 重组溶瘤性ii型单纯疱疹病毒及其药物组合物
AU2016232771B2 (en) * 2015-03-18 2021-08-19 Omnicyte Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
CN105343874A (zh) * 2015-11-11 2016-02-24 固安鼎泰海规生物科技有限公司 一种前列腺癌核酸疫苗
CN107281475B (zh) * 2017-06-15 2020-12-25 杭州贝罗康生物技术有限公司 一种预防及治疗肿瘤的基因疫苗及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
EP0974357A1 (fr) * 1998-07-16 2000-01-26 Schering-Plough Chemokines comme adjuvants de la réponse immunitaire
EP1156823B1 (fr) * 1999-02-12 2008-10-29 The Scripps Research Institute Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies
WO2001027146A2 (fr) * 1999-10-12 2001-04-19 Chemocentryx, Inc. Recepteur de chemokine
WO2001040311A1 (fr) * 1999-11-30 2001-06-07 Shionogi & Co., Ltd. Proteine fusionnee de chimiokine slc-il2
EP1118331A1 (fr) * 2000-01-21 2001-07-25 I.D.M. Immuno-Designed Molecules Méthode pour augmenter la présentation d'antigène exogène par les cellules humaines présentatrices d'antigène et complexes de microparticules opsonisées pour appliquer cette méthode
WO2002034287A2 (fr) * 2000-10-27 2002-05-02 Pharmexa A/S Nouvelles formulations de vaccin therapeutique
MXPA03006587A (es) * 2001-01-24 2003-09-22 Schering Corp Quimiocinas como adyuvantes de respuesta inmune.
EP1256354A1 (fr) * 2001-05-11 2002-11-13 Schering Corporation Methodes pour le traitement du cancer
WO2003055439A2 (fr) * 2001-07-18 2003-07-10 The Regents Of The University Of California Antigene cible her2/neu et son utilisation pour stimuler une reponse immunitaire

Also Published As

Publication number Publication date
JP2007535949A (ja) 2007-12-13
CN100342017C (zh) 2007-10-10
US20090209729A1 (en) 2009-08-20
CA2566299A1 (fr) 2005-11-17
EP1748075A4 (fr) 2008-01-02
RU2396348C2 (ru) 2010-08-10
CA2566299C (fr) 2011-12-06
EP1748075A8 (fr) 2007-09-26
CN1696293A (zh) 2005-11-16
ES2343419T3 (es) 2010-07-30
US8133873B2 (en) 2012-03-13
JP4838238B2 (ja) 2011-12-14
RU2006142760A (ru) 2008-06-20
AU2005240691A1 (en) 2005-11-17
ATE462792T1 (de) 2010-04-15
PL1748075T3 (pl) 2010-09-30
AU2005240691B2 (en) 2009-06-04
DE602005020272D1 (de) 2010-05-12
WO2005108584A1 (fr) 2005-11-17
EP1748075B1 (fr) 2010-03-31
HK1102076A1 (en) 2007-11-02

Similar Documents

Publication Publication Date Title
US5262177A (en) Recombinant viruses encoding the human melanoma-associated antigen
AU2004215489B2 (en) Modified antibody
EP1037927B1 (fr) Proteines de fusion heterodymeres utiles en therapie immune ciblee et a une stimulation immune generale
KR100689739B1 (ko) 단백질 및 펩티드 항원의 면역원성을 증강시키는 Ｆｃ융합 단백질
MXPA02001417A (es) Complejos multiples de citosina-anticuerpo.
JP2007297398A (ja) 突然変異上皮成長因子受容体を標的とする試薬および方法
JP2008523818A (ja) 腫瘍免疫療法におけるフラジェリンの使用
CN110054698B (zh) 抗cd19抗体的新型cd19-car载体的构建及应用
AT500650B1 (de) Immunogener rekombinanter antikörper
CN113088495A (zh) 工程改造的t细胞、其制备及应用
CN116284419B (zh) 靶向人gucy2c蛋白的单克隆抗体及其应用
EP1748075B1 (fr) Vaccin chimiokine-antigene recombinant
AU754505B2 (en) Biological material for preparing pharmaceutical compositions for treating mammals
JP2001504695A (ja) ウシ泌乳関連向免疫性タンパク質（ｃｄ１４）、コード遺伝子、およびｂ細胞活性化における適用
EP1496937B1 (fr) Vaccin adn combiné avec un inducteur de l'apoptose de cellules tumorales
HK1102076B (en) Recombinant chemokine-antigen vaccine
CN101094686A (zh) 鞭毛蛋白在肿瘤免疫疗法中的用途
AU782853B2 (en) Methods for preventing or attenuating pathoangiogenic conditions
FI104424B (fi) Menetelmä onkostatiini M -mutantin valmistamiseksi
Visseren et al. Production of interleukin-2 by EL4 tumor cells induces natural killer cell-and T-cell-mediated immunity
IE59597B1 (en) Vaccines against melanoma
EP4577562A1 (fr) Immunothérapie à base d'épitopes dérivés de magea1
CN113005088A (zh) 工程改造的t细胞、其制备及应用
HK40086477A (zh) 提高nk细胞存活和抗肿瘤活性的方法及应用
CN114369581A (zh) 一种具有抗肿瘤免疫功能重组腺病毒、制备方法及应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MA, WENBO

Inventor name: SUN, WENXIN

Inventor name: FU, MING

Inventor name: LIN, CHEN

Inventor name: LIANG, XIAO

Inventor name: ZHANG, SHUREN

Inventor name: WANG, DONGMEI

Inventor name: ZHOU, CHUNXIA

Inventor name: ZHANG, XUEYAN

Inventor name: QIN, HANJUN

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102076

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CANCER INSTITUTE, CHINESE ACADEMY OF MEDICAL SCIEN

A4 Supplementary search report drawn up and despatched

Effective date: 20071130

17Q First examination report despatched

Effective date: 20080401

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005020272

Country of ref document: DE

Date of ref document: 20100512

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100331

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1102076

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2343419

Country of ref document: ES

Kind code of ref document: T3

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100731

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100802

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

26N No opposition filed

Effective date: 20110104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100509

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120523

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20130524

Year of fee payment: 9

Ref country code: GB

Payment date: 20130426

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20130502

Year of fee payment: 9

Ref country code: FR

Payment date: 20130621

Year of fee payment: 9

Ref country code: IT

Payment date: 20130527

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005020272

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140509

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005020272

Country of ref document: DE

Effective date: 20141202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140509

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140509

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140602

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140509

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE